Drug Profile
Research programme: protein therapeutics - Nostrum Pharmaceuticals
Alternative Names: Caerulomycin ALatest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Institute of Microbial Technology
- Developer Nostrum Pharmaceuticals
- Class Proteins; Pyridines; Small molecules
- Mechanism of Action Immunosuppressants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Autoimmune disorders; Transplant rejection
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Autoimmune-disorders in India
- 16 Jul 2016 No recent reports of development identified for preclinical development in Transplant-rejection in India
- 26 Feb 2009 Preclinical trials in Autoimmune disorders in India (unspecified route)